Blog

DeepHRD predicts HRD from routine biopsy slides

Photo from Erik Bergstrom/LinkedIn

Aug 6, 2024, 14:09

DeepHRD predicts HRD from routine biopsy slides

Elvina Almuradova, Medical Oncologist Ambassador at European School of Oncology, shared a post on X, about recent paper published in Journal of Clinical Oncology:

Deep Learning Artificial Intelligence Predicts Homologous Recombination Deficiency and Platinum Response From Histologic Slides.

Authors: Erik N. Bergstrom, Ammal Abbasi, Marcos Díaz-Gay, Loïck Galland, Sylvain Ladoire, Scott M. Lippman, Ludmil B. Alexandrov.

Elvina Almuradova

”DeepHRD, a new AI tool, predicts homologous recombination deficiency from routine biopsy slides. In studies, it outperformed traditional tests, predicting better outcomes for breast and ovarian cancer patients.”

Source: Elvina Almuradova/X

Ammal Abbasi Breast Cancer cancer Elvina Almuradova Erik N. Bergstrom European School of Oncology homologous recombination deficiency Journal of Clinical Oncology Loïck Galland Ludmil B. Alexandrov Marcos Díaz-Gay OncoDaily Oncology Ovarian Cancer Scott M. Lippman Sylvain Ladoire

NEW PAPER ALERT: Efficacy of CDK4/6 Inhibitors and Endocrine Therapy in HR+/HER2- Advanced Breast Cancer by PAM50 Subtype: SOLTI-1801 CDK-PREDICT Results

Oncologist Near Me – Fabrice André: Leading Expert in Breast Cancer

Funding Impactful Cancer Research That Might Otherwise Go Unsupported: Ryan Schoenfeld on the Secret Behind Mark Foundation’s Success

One Hand Gives, Another Takes? Trump, Musk, Congress and Childhood Cancer Research Funding

Fabrice André has been elected as the President of the ESMO for the term 2025-2026

Special Coverage